{"protocolSection":{"identificationModule":{"nctId":"NCT02459262","orgStudyIdInfo":{"id":"2014-004542-10"},"secondaryIdInfos":[{"id":"2014","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2014"}],"organization":{"fullName":"Minervax ApS","class":"OTHER"},"briefTitle":"Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.","officialTitle":"A Two-part, Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of a Dose Range og Group B Streptococcus Vaccine in Healthy Female Volunteers Aged 18 to 40.","acronym":"MVX13211"},"statusModule":{"statusVerifiedDate":"2020-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-05"},"primaryCompletionDateStruct":{"date":"2017-04-12","type":"ACTUAL"},"completionDateStruct":{"date":"2017-04-21","type":"ACTUAL"},"studyFirstSubmitDate":"2015-05-22","studyFirstSubmitQcDate":"2015-05-28","studyFirstPostDateStruct":{"date":"2015-06-02","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-11-30","resultsFirstSubmitQcDate":"2021-01-12","resultsFirstPostDateStruct":{"date":"2021-01-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-01-12","lastUpdatePostDateStruct":{"date":"2021-01-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Minervax ApS","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Part A: The primary objective is to evaluate the safety and tolerability of a potential vaccine against Group B streptococcus.\n\nPart B: To evaluate the long term safety profile of the GBS-NN vaccine up to one year following the first dose.","detailedDescription":"Part A: Subjects will receive 2 doses of the vaccine, GBS-NN, and will be followed for 12 weeks after the first dose of the vaccine. The following safety endpoints will be evaluated to support this objective: local and systemic reactogenicity; adverse events; laboratory tests; urinalysis; vital signs; 12-Lead ECG parameters; physical examination. In addition hereto, immunological parameters will be evaluated.\n\nPart B: Subjects will receive one or 2 doses of GBS-NN, and will be followed for 12 months after the first dose of the vaccine. The following safety endpoints will be evaluated to support this objective: local and systemic reactogenicity; adverse events; laboratory tests; urinalysis; vital signs; 12-Lead ECG parameters; physical examination. In addition hereto, immunological parameters will be evaluated."},"conditionsModule":{"conditions":["Infection by Streptococcus Group B"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":240,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"GBS-NN Vaccine","type":"ACTIVE_COMPARATOR","description":"GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.","interventionNames":["Biological: GBS-NN vaccine"]},{"label":"Sterile dilution buffer with Alhydrogel","type":"PLACEBO_COMPARATOR","description":"The placebo will contain either Alhydrogel® or buffer alone.","interventionNames":["Biological: GBS-NN vaccine"]}],"interventions":[{"type":"BIOLOGICAL","name":"GBS-NN vaccine","description":"Three dose levels will be administered, with and without Alhydrogel®","armGroupLabels":["GBS-NN Vaccine","Sterile dilution buffer with Alhydrogel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part A Number of Participants With Treatment Emergent Adverse Events","description":"Number of Participants with Treatment Emergent Adverse Events","timeFrame":"12 weeks (to Day 85)"},{"measure":"Part B Number of Participants With Treatment Emergent Adverse Events","description":"Number of Participants with Treatment Emergent Adverse Events","timeFrame":"12 weeks (to Day 85)"}],"secondaryOutcomes":[{"measure":"Part A Antibody Concentration","description":"Geometric mean antibody concentration","timeFrame":"12 weeks (Day 85)"},{"measure":"Part B Antibody Concentration","description":"Geometric mean antibody concentration","timeFrame":"12 weeks (Day 85)"},{"measure":"Part B Antibody Concentration","description":"Geometric mean antibody concentration","timeFrame":"1 year (Day 365)"},{"measure":"Part B Number of Participants With Treatment Emergent Adverse Events","description":"Number of Participants with Treatment Emergent Adverse Events","timeFrame":"Day 85 to Day 365"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy adult female volunteers (as determined by medical history, physical examination, laboratory test values, vital signs and electrocardiograms \\[ECGs\\] at screening) aged 18 - 40 years.\n2. Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2.\n3. Volunteers weight ≥ 50kg and ≤100kg at screening.\n4. Able to voluntarily provide written informed consent to participate in the study.\n5. Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol.\n6. Volunteers must be pre-menopausal. Volunteers who have had a hysterectomy will have pre-menopausal status confirmed by a FSH and oestradiol test.\n7. Females of childbearing potential must have a negative pregnancy test at screening (β HCG) and prior to each dose and must be willing to use an adequate and highly effective method of contraception until at least Day 85 of the study. A highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, IUDs (Intrauterine Device), condoms, occlusive caps (cervical/vault caps) with spermicidal foam/gel/ film/cream/suppository. True sexual abstinence is acceptable when this is in line with the preferred and usual lifestyle of the volunteer (periodic abstinence e.g. calendar, ovulation, symptothermal, post-ovulation methods, declaration of abstinence for the duration of the trial, and withdrawal are not acceptable methods of contraception)\n8. In Part A: Volunteers must be non-smokers for at least 3 months prior to first studyvaccine administration. In Part B: Volunteers may be light smokers i.e. up to a maximum of 5 cigarettes per day or nicotine equivalent.\n9. Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).\n10. The volunteer's primary care physician has confirmed within the last 12 months that there is nothing in their medical history that would preclude their enrolment into a clinical trial.\n\nExclusion Criteria:\n\n1. Volunteers with history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, psychiatric, autoimmune disease or current infection.\n2. Pregnant or lactating females.\n3. Laboratory values at screening which are deemed to be clinically significant, unless agreed in advance by the Sponsor's Responsible Medic and Principal Investigator.\n4. Current or history of drug or alcohol abuse, or a positive alcohol breath test prior to first dosing.\n5. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.\n6. Participation in a clinical drug study during the 90 days preceding the initial dose in this study.\n7. Any significant illness during the 4 weeks preceding check-in for this study (Day 1).\n8. Volunteers with a history of severe allergic reactions after previous vaccination.\n9. Volunteers who have received any vaccine within 30 days of screening, or who are planning to receive a vaccine up to Day 85 of the study.\n10. Volunteers receiving immunosuppressive therapy (e.g. systemic steroids, cancer therapies, methotrexate, azathioprine) in the 6 months prior to screening, antibiotics within 10 days of receiving the first dose or taking any short-term medications including over-the-counter preparations, vitamins, herbal and/or mineral supplements within 7 days of the first dose. Chronic medications such as antihypertensives, bronchodilators, oral contraceptives or statins that do not affect the immune system, will be permitted and allowed to continue during the study at the discretion of the Investigator. Paracetamol will be permitted for the treatment of headache or other symptoms.\n11. Volunteers with tattoos at the proposed site of vaccine administration.\n12. Donation of blood or blood products within 90 days prior to vaccine administration.\n13. Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Per Fisher, PM/CEO","affiliation":"MinervaX ApS, Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Biokinetic Europ Ltd","city":"Belfast","zip":"BT2 7BA","country":"United Kingdom","geoPoint":{"lat":54.59682,"lon":-5.92541}}]},"referencesModule":{"references":[{"pmid":"35243418","type":"DERIVED","citation":"Pawlowski A, Lannergard J, Gonzalez-Miro M, Cao D, Larsson S, Persson JJ, Kitson G, Darsley M, Rom AL, Hedegaard M, Fischer PB, Johansson-Lindbom B. A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains. Cell Rep Med. 2022 Feb 15;3(2):100511. doi: 10.1016/j.xcrm.2022.100511. eCollection 2022 Feb 15."},{"pmid":"34215454","type":"DERIVED","citation":"Fischer P, Pawlowski A, Cao D, Bell D, Kitson G, Darsley M, Johansson-Lindbom B. Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women. Vaccine. 2021 Jul 22;39(32):4489-4499. doi: 10.1016/j.vaccine.2021.06.046. Epub 2021 Jun 30."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Part A was the dose-finding part of the study and 60 healthy female participants received either 2 doses of GBS-NN 10mcg, 50mcg, 250mcg or placebo (4:1 ratio of active:placebo). Based on the 8 week (Day 57) antibody levels from Part A, 180 healthy female participants in Part B were recruited to receive either 2 doses of GBS-NN 50mcg, 2 doses of GBS-NN 100mcg, 1 dose of GBS-NN 100mcg or placebo (3:1 ratio of active to placebo). Participants in Part A were not allowed to participate In Part B.","recruitmentDetails":"Part A: Healthy females were recruited to receive two doses of either GBS-NN vaccine with or without Alhydrogel® gel adjuvant at three dose levels (10mcg, 50mcg, 250mcg) or placebo.\n\nPart B: Doses of 50mcg (2 doses) and 100mcg (1 and 2 doses) were selected from the antibody levels at 8 weeks from Part A and vaccine was administered with Alhydrogel®. Participants were healthy females and did not include participants from Part A. They were followed up for 1 year.","groups":[{"id":"FG000","title":"Part A GBS-NN Vaccine 10mcg","description":"GBS-NN 10mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"FG001","title":"Part A GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"FG002","title":"Part A GBS-NN Vaccine 250mcg","description":"GBS-NN 250mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"FG003","title":"Part A GBS-NN 10mcg Vaccine Administered With Alhydrogel® Adjuvant","description":"GBS-NN 10mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"FG004","title":"Part A GBS-NN 50mcg Vaccine Administered With Alhydrogel® Adjuvant","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"FG005","title":"Part A GBS-NN 250mcg Vaccine Administered With Alhydrogel® Adjuvant","description":"GBS-NN 250mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"FG006","title":"Part A Placebo","description":"Alhydrogel® mixed with dilution buffer or buffer alone administered by intramuscular injection"},{"id":"FG007","title":"Part B GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"FG008","title":"Part B GBS-NN Vaccine 100mcg 2 Dose Regimen","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"FG009","title":"Part B GBS-NN Vaccine 100mcg Single Dose","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1"},{"id":"FG010","title":"Part B Placebo","description":"Alhydrogel® mixed with dilution buffer and administered by intramuscular injection"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"45"},{"groupId":"FG008","numSubjects":"45"},{"groupId":"FG009","numSubjects":"45"},{"groupId":"FG010","numSubjects":"45"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"45"},{"groupId":"FG008","numSubjects":"45"},{"groupId":"FG009","numSubjects":"44"},{"groupId":"FG010","numSubjects":"45"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Part A GBS-NN Vaccine 10mcg","description":"GBS-NN 10mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"BG001","title":"Part A GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"BG002","title":"Part A GBS-NN Vaccine 250mcg","description":"GBS-NN 250mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"BG003","title":"Part A GBS-NN Vaccine 10mcg With Alhydrogel® Adjuvant","description":"GBS-NN 10 mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"BG004","title":"Part A GBS-NN Vaccine 50mcg With Alhydrogel® Adjuvant","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"BG005","title":"Part A GBS-NN Vaccine 250mcg With Alhydrogel® Adjuvant","description":"GBS-NN 250mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"BG006","title":"Part A Placebo","description":"Alhydrogel® mixed with dilution buffer or buffer alone administered by intramuscular injection"},{"id":"BG007","title":"Part B GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"BG008","title":"Part B GBS-NN Vacine 100mcg 2 Dose Regimen","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"BG009","title":"Part B GBS-NN Vacine 100mcg Single Dose","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1"},{"id":"BG010","title":"Part B Placebo","description":"Alhydrogel® mixed with dilution buffer and administered by intramuscular injection"},{"id":"BG011","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"45"},{"groupId":"BG008","value":"45"},{"groupId":"BG009","value":"45"},{"groupId":"BG010","value":"45"},{"groupId":"BG011","value":"240"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28.6","spread":"4.8"},{"groupId":"BG001","value":"29.3","spread":"6.6"},{"groupId":"BG002","value":"30.4","spread":"5.0"},{"groupId":"BG003","value":"28.3","spread":"7.4"},{"groupId":"BG004","value":"31.3","spread":"4.5"},{"groupId":"BG005","value":"30.4","spread":"5.7"},{"groupId":"BG006","value":"28.5","spread":"6.6"},{"groupId":"BG007","value":"29.0","spread":"6.3"},{"groupId":"BG008","value":"30.3","spread":"6.0"},{"groupId":"BG009","value":"29.4","spread":"6.5"},{"groupId":"BG010","value":"28.7","spread":"6.5"},{"groupId":"BG011","value":"29.5","spread":"6.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"45"},{"groupId":"BG008","value":"45"},{"groupId":"BG009","value":"45"},{"groupId":"BG010","value":"45"},{"groupId":"BG011","value":"240"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"1"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"45"},{"groupId":"BG008","value":"45"},{"groupId":"BG009","value":"45"},{"groupId":"BG010","value":"44"},{"groupId":"BG011","value":"239"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"45"},{"groupId":"BG008","value":"45"},{"groupId":"BG009","value":"45"},{"groupId":"BG010","value":"44"},{"groupId":"BG011","value":"239"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"45"},{"groupId":"BG008","value":"45"},{"groupId":"BG009","value":"45"},{"groupId":"BG010","value":"45"},{"groupId":"BG011","value":"240"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part A Number of Participants With Treatment Emergent Adverse Events","description":"Number of Participants with Treatment Emergent Adverse Events","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"12 weeks (to Day 85)","groups":[{"id":"OG000","title":"Part A GBS-NN Vaccine 10mcg","description":"GBS-NN 10mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG001","title":"Part A GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG002","title":"Part A GBS-NN Vaccine 250mcg","description":"GBS-NN 250mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG003","title":"Part A GBS-NN Vaccine 10mcg With Alhydrogel® Adjuvant","description":"GBS-NN 10 mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG004","title":"Part A GBS-NN Vaccine 50mcg With Alhydrogel® Adjuvant","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG005","title":"Part A GBS-NN Vaccine 250mcg With Alhydrogel® Adjuvant","description":"GBS-NN 250mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG006","title":"Part A Placebo","description":"Alhydrogel® mixed with dilution buffer or buffer alone administered by intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"11"}]}]}]},{"type":"PRIMARY","title":"Part B Number of Participants With Treatment Emergent Adverse Events","description":"Number of Participants with Treatment Emergent Adverse Events","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"12 weeks (to Day 85)","groups":[{"id":"OG000","title":"Part B GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG001","title":"Part B GBS-NN Vacine 100mcg 2 Dose Regimen","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG002","title":"Part B GBS-NN Vacine 100mcg Single Dose","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1"},{"id":"OG003","title":"Part B Placebo","description":"Alhydrogel® mixed with dilution buffer and administered by intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"37"}]}]}]},{"type":"SECONDARY","title":"Part A Antibody Concentration","description":"Geometric mean antibody concentration","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Full Range","unitOfMeasure":"mcg/mL","timeFrame":"12 weeks (Day 85)","groups":[{"id":"OG000","title":"Part A GBS-NN Vaccine 10mcg","description":"GBS-NN 10mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG001","title":"Part A GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG002","title":"Part A GBS-NN Vaccine 250mcg","description":"GBS-NN 250mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG003","title":"Part A GBS-NN Vaccine 10mcg With Alhydrogel® Adjuvant","description":"GBS-NN 10 mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG004","title":"Part A GBS-NN Vaccine 50mcg With Alhydrogel® Adjuvant","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG005","title":"Part A GBS-NN Vaccine 250mcg With Alhydrogel® Adjuvant","description":"GBS-NN 250mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG006","title":"Part A Placebo","description":"Alhydrogel® mixed with dilution buffer or buffer alone administered by intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.977","lowerLimit":"0.021","upperLimit":"35.80"},{"groupId":"OG001","value":"2.926","lowerLimit":"0.27","upperLimit":"17.40"},{"groupId":"OG002","value":"7.195","lowerLimit":"0.865","upperLimit":"106"},{"groupId":"OG003","value":"16.864","lowerLimit":"1.11","upperLimit":"263"},{"groupId":"OG004","value":"14.999","lowerLimit":"2.95","upperLimit":"83.00"},{"groupId":"OG005","value":"25.431","lowerLimit":"0.59","upperLimit":"277"},{"groupId":"OG006","value":"0.199","lowerLimit":"0.03","upperLimit":"1.61"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002","OG003","OG004","OG005","OG006"],"groupDescription":"The objectives for Part A were to evaluate the effect of adjuvant and to inform the selection of dose levels for Part B. The study was not powered for inter-group comparisons.","nonInferiorityType":"OTHER","nonInferiorityComment":"ANOVA repeated measures: In-transformed antibody concentrations as dependent variable; dose level, time, presence of adjuvant and dose\\*time interaction as fixed effects; subjects as random effects","pValue":"0.0193","pValueComment":"Adjuvant effect at Day 85, the primary immunological endpoint","statisticalMethod":"ANOVA","statisticalComment":"Adjuvant effect, with higher antibody concentration values after all dose levels of vaccine was significant at all time points (D29, D43, D57, Day 85)"}]},{"type":"SECONDARY","title":"Part B Antibody Concentration","description":"Geometric mean antibody concentration","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Full Range","unitOfMeasure":"mcg/mL","timeFrame":"12 weeks (Day 85)","groups":[{"id":"OG000","title":"Part B GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG001","title":"Part B GBS-NN Vacine 100mcg 2 Dose Regimen","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG002","title":"Part B GBS-NN Vacine 100mcg Single Dose","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1"},{"id":"OG003","title":"Part B Placebo","description":"Alhydrogel® mixed with dilution buffer and administered by intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.914","lowerLimit":"0.90","upperLimit":"247.00"},{"groupId":"OG001","value":"15.459","lowerLimit":"0.35","upperLimit":"314.00"},{"groupId":"OG002","value":"3.035","lowerLimit":"0.17","upperLimit":"50.20"},{"groupId":"OG003","value":"0.234","lowerLimit":"0.03","upperLimit":"15.80"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002","OG003"],"nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"ANOVA"}]},{"type":"SECONDARY","title":"Part B Antibody Concentration","description":"Geometric mean antibody concentration","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Full Range","unitOfMeasure":"mcg/mL","timeFrame":"1 year (Day 365)","groups":[{"id":"OG000","title":"Part B GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG001","title":"Part B GBS-NN Vacine 100mcg 2 Dose Regimen","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG002","title":"Part B GBS-NN Vacine 100mcg Single Dose","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1"},{"id":"OG003","title":"Part B Placebo","description":"Alhydrogel® mixed with dilution buffer and administered by intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.201","lowerLimit":"0.24","upperLimit":"58.40"},{"groupId":"OG001","value":"5.934","lowerLimit":"0.20","upperLimit":"314.00"},{"groupId":"OG002","value":"1.596","lowerLimit":"0.06","upperLimit":"117.00"},{"groupId":"OG003","value":"0.263","lowerLimit":"0.03","upperLimit":"50.50"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002","OG003"],"nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"ANOVA"}]},{"type":"SECONDARY","title":"Part B Number of Participants With Treatment Emergent Adverse Events","description":"Number of Participants with Treatment Emergent Adverse Events","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 85 to Day 365","groups":[{"id":"OG000","title":"Part B GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG001","title":"Part B GBS-NN Vacine 100mcg 2 Dose Regimen","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29"},{"id":"OG002","title":"Part B GBS-NN Vacine 100mcg Single Dose","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1"},{"id":"OG003","title":"Part B Placebo","description":"Alhydrogel® mixed with dilution buffer and administered by intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"21"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Part A: to 12 weeks (D85) Part B: to 12 weeks (D85)","eventGroups":[{"id":"EG000","title":"Part A GBS-NN Vaccine 10mcg","description":"GBS-NN 10mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":6,"otherNumAtRisk":8},{"id":"EG001","title":"Part A GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":5,"otherNumAtRisk":8},{"id":"EG002","title":"Part A GBS-NN Vaccine 250mcg","description":"GBS-NN 250mcg vaccine administered without Alhydrogel® by intramuscular injection on Day 1 and Day 29","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":5,"otherNumAtRisk":8},{"id":"EG003","title":"Part A GBS-NN Vaccine 10mcg With Alhydrogel® Adjuvant","description":"GBS-NN 10 mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":6,"otherNumAtRisk":8},{"id":"EG004","title":"Part A GBS-NN Vaccine 50mcg With Alhydrogel® Adjuvant","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":8,"otherNumAtRisk":8},{"id":"EG005","title":"Part A GBS-NN Vaccine 250mcg With Alhydrogel® Adjuvant","description":"GBS-NN 250mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":8,"otherNumAtRisk":8},{"id":"EG006","title":"Part A Placebo","description":"Alhydrogel® mixed with dilution buffer or buffer alone administered by intramuscular injection","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG007","title":"Part B GBS-NN Vaccine 50mcg","description":"GBS-NN 50mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29","deathsNumAffected":0,"deathsNumAtRisk":45,"seriousNumAffected":0,"seriousNumAtRisk":45,"otherNumAffected":41,"otherNumAtRisk":45},{"id":"EG008","title":"Part B GBS-NN Vacine 100mcg 2 Dose Regimen","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1 and Day 29","deathsNumAffected":0,"deathsNumAtRisk":45,"seriousNumAffected":0,"seriousNumAtRisk":45,"otherNumAffected":39,"otherNumAtRisk":45},{"id":"EG009","title":"Part B GBS-NN Vacine 100mcg Single Dose","description":"GBS-NN 100mcg vaccine administered with Alhydrogel® by intramuscular injection on Day 1","deathsNumAffected":0,"deathsNumAtRisk":45,"seriousNumAffected":0,"seriousNumAtRisk":45,"otherNumAffected":31,"otherNumAtRisk":45},{"id":"EG010","title":"Part B Placebo","description":"Alhydrogel® mixed with dilution buffer and administered by intramuscular injection","deathsNumAffected":0,"deathsNumAtRisk":45,"seriousNumAffected":1,"seriousNumAtRisk":45,"otherNumAffected":37,"otherNumAtRisk":45}],"seriousEvents":[{"term":"Spontaneous abortion","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":45},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":45}]}],"otherEvents":[{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":8},{"groupId":"EG003","numAffected":6,"numAtRisk":8},{"groupId":"EG004","numAffected":4,"numAtRisk":8},{"groupId":"EG005","numAffected":4,"numAtRisk":8},{"groupId":"EG006","numAffected":4,"numAtRisk":12},{"groupId":"EG007","numAffected":26,"numAtRisk":45},{"groupId":"EG008","numAffected":26,"numAtRisk":45},{"groupId":"EG009","numAffected":16,"numAtRisk":45},{"groupId":"EG010","numAffected":18,"numAtRisk":45}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":3,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":8},{"groupId":"EG003","numAffected":2,"numAtRisk":8},{"groupId":"EG004","numAffected":2,"numAtRisk":8},{"groupId":"EG005","numAffected":1,"numAtRisk":8},{"groupId":"EG006","numAffected":4,"numAtRisk":12},{"groupId":"EG007","numAffected":14,"numAtRisk":45},{"groupId":"EG008","numAffected":9,"numAtRisk":45},{"groupId":"EG009","numAffected":6,"numAtRisk":45},{"groupId":"EG010","numAffected":11,"numAtRisk":45}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":0,"numAtRisk":8},{"groupId":"EG006","numAffected":3,"numAtRisk":12},{"groupId":"EG007","numAffected":2,"numAtRisk":45},{"groupId":"EG008","numAffected":3,"numAtRisk":45},{"groupId":"EG009","numAffected":2,"numAtRisk":45},{"groupId":"EG010","numAffected":1,"numAtRisk":45}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":1,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":8},{"groupId":"EG005","numAffected":0,"numAtRisk":8},{"groupId":"EG006","numAffected":1,"numAtRisk":12},{"groupId":"EG007","numAffected":15,"numAtRisk":45},{"groupId":"EG008","numAffected":7,"numAtRisk":45},{"groupId":"EG009","numAffected":12,"numAtRisk":45},{"groupId":"EG010","numAffected":5,"numAtRisk":45}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":1,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":1,"numAtRisk":8},{"groupId":"EG006","numAffected":0,"numAtRisk":12},{"groupId":"EG007","numAffected":1,"numAtRisk":45},{"groupId":"EG008","numAffected":2,"numAtRisk":45},{"groupId":"EG009","numAffected":1,"numAtRisk":45},{"groupId":"EG010","numAffected":2,"numAtRisk":45}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":8},{"groupId":"EG003","numAffected":1,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":0,"numAtRisk":8},{"groupId":"EG006","numAffected":1,"numAtRisk":12},{"groupId":"EG007","numAffected":0,"numAtRisk":45},{"groupId":"EG008","numAffected":0,"numAtRisk":45},{"groupId":"EG009","numAffected":0,"numAtRisk":45},{"groupId":"EG010","numAffected":0,"numAtRisk":45}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":8},{"groupId":"EG005","numAffected":0,"numAtRisk":8},{"groupId":"EG006","numAffected":2,"numAtRisk":12},{"groupId":"EG007","numAffected":2,"numAtRisk":45},{"groupId":"EG008","numAffected":2,"numAtRisk":45},{"groupId":"EG009","numAffected":1,"numAtRisk":45},{"groupId":"EG010","numAffected":4,"numAtRisk":45}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":1,"numAtRisk":8},{"groupId":"EG006","numAffected":1,"numAtRisk":12},{"groupId":"EG007","numAffected":0,"numAtRisk":45},{"groupId":"EG008","numAffected":0,"numAtRisk":45},{"groupId":"EG009","numAffected":0,"numAtRisk":45},{"groupId":"EG010","numAffected":0,"numAtRisk":45}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":8},{"groupId":"EG003","numAffected":2,"numAtRisk":8},{"groupId":"EG004","numAffected":6,"numAtRisk":8},{"groupId":"EG005","numAffected":2,"numAtRisk":8},{"groupId":"EG006","numAffected":2,"numAtRisk":12},{"groupId":"EG007","numAffected":2,"numAtRisk":45},{"groupId":"EG008","numAffected":2,"numAtRisk":45},{"groupId":"EG009","numAffected":0,"numAtRisk":45},{"groupId":"EG010","numAffected":5,"numAtRisk":45}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":3,"numAtRisk":8},{"groupId":"EG006","numAffected":0,"numAtRisk":12},{"groupId":"EG007","numAffected":0,"numAtRisk":45},{"groupId":"EG008","numAffected":0,"numAtRisk":45},{"groupId":"EG009","numAffected":0,"numAtRisk":45},{"groupId":"EG010","numAffected":0,"numAtRisk":45}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":8},{"groupId":"EG005","numAffected":1,"numAtRisk":8},{"groupId":"EG006","numAffected":1,"numAtRisk":12},{"groupId":"EG007","numAffected":2,"numAtRisk":45},{"groupId":"EG008","numAffected":2,"numAtRisk":45},{"groupId":"EG009","numAffected":2,"numAtRisk":45},{"groupId":"EG010","numAffected":3,"numAtRisk":45}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":1,"numAtRisk":8},{"groupId":"EG006","numAffected":1,"numAtRisk":12},{"groupId":"EG007","numAffected":1,"numAtRisk":45},{"groupId":"EG008","numAffected":1,"numAtRisk":45},{"groupId":"EG009","numAffected":0,"numAtRisk":45},{"groupId":"EG010","numAffected":3,"numAtRisk":45}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":0,"numAtRisk":8},{"groupId":"EG006","numAffected":0,"numAtRisk":12},{"groupId":"EG007","numAffected":2,"numAtRisk":45},{"groupId":"EG008","numAffected":0,"numAtRisk":45},{"groupId":"EG009","numAffected":1,"numAtRisk":45},{"groupId":"EG010","numAffected":1,"numAtRisk":45}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":0,"numAtRisk":8},{"groupId":"EG006","numAffected":0,"numAtRisk":12},{"groupId":"EG007","numAffected":4,"numAtRisk":45},{"groupId":"EG008","numAffected":2,"numAtRisk":45},{"groupId":"EG009","numAffected":2,"numAtRisk":45},{"groupId":"EG010","numAffected":0,"numAtRisk":45}]},{"term":"Vulvovaginal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":0,"numAtRisk":8},{"groupId":"EG006","numAffected":0,"numAtRisk":12},{"groupId":"EG007","numAffected":1,"numAtRisk":45},{"groupId":"EG008","numAffected":1,"numAtRisk":45},{"groupId":"EG009","numAffected":1,"numAtRisk":45},{"groupId":"EG010","numAffected":1,"numAtRisk":45}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":0,"numAtRisk":8},{"groupId":"EG006","numAffected":0,"numAtRisk":12},{"groupId":"EG007","numAffected":2,"numAtRisk":45},{"groupId":"EG008","numAffected":2,"numAtRisk":45},{"groupId":"EG009","numAffected":1,"numAtRisk":45},{"groupId":"EG010","numAffected":0,"numAtRisk":45}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":0,"numAtRisk":8},{"groupId":"EG006","numAffected":0,"numAtRisk":12},{"groupId":"EG007","numAffected":2,"numAtRisk":45},{"groupId":"EG008","numAffected":2,"numAtRisk":45},{"groupId":"EG009","numAffected":3,"numAtRisk":45},{"groupId":"EG010","numAffected":1,"numAtRisk":45}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":8},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":8},{"groupId":"EG005","numAffected":0,"numAtRisk":8},{"groupId":"EG006","numAffected":0,"numAtRisk":12},{"groupId":"EG007","numAffected":3,"numAtRisk":45},{"groupId":"EG008","numAffected":1,"numAtRisk":45},{"groupId":"EG009","numAffected":1,"numAtRisk":45},{"groupId":"EG010","numAffected":3,"numAtRisk":45}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Per Fisher DPhil","organization":"MinervaX ApS","email":"pbf@minervax.com","phone":"+45 20 25 20 38"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2015-11-30","uploadDate":"2020-11-30T07:16","filename":"Prot_SAP_000.pdf","size":1862845}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"}},"hasResults":true}